GE's PET amyloid imaging agent, flutemetamol, will be part of the trail that evaluates Eisai's investigational compound E2609, a BACE (beta-site amyloid precursor protein-cleaving enzyme) inhibitor for the potential treatment of Alzheimer's. Imaging agents like flutemetamol are used in the visual detection of beta-amyloid, which is associated with Alzheimer's disease.
Story Continues Below Advertisement
Ad Statistics
Times Displayed: 22749
Times Visited: 262
Stretcher pads & mattress discounts for DOTmed users, call (800)448-6163
North America Mattress Corp. offers best pricing for replacement pads and mattresses. Buy direct from the manufacture and save.
Under terms of the agreement, GE Healthcare's proprietary software technology will be used during the trial to help support imaging data analysis.
"This partnership may ultimately support the market entry of important therapies, and potentially, expedited time to market because the right patients have been identified for participation in clinical trials," said Pascale Witz, president and CEO of GE Healthcare's medical diagnostics division, in a statement.
In January, the U.S. Food and Drug Administration announced that it has accepted GE's application to review flutemetamol. Eli Lilly & Co.'s Amyvid, which it acquired through a deal with a Siemens subsidiary, received FDA approval in the spring of 2012. It's currently the only available PET imaging agent to measure beta-amyloid plaque in patients with suspected Alzheimer's disease.
GE said that by collaborating with the pharmaceutical industry to assist in their development of the next generation of therapies to treat disorders like Alzheimer's, and working with potential partners in the industry, the company can provide imaging support for clinical trials of therapeutic agents.
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEiyUJiDaZC_rvV-QEuEDyGiX_uvQ&url=http://www.dotmed.com/news/story/20956/
0 comments:
Post a Comment